OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+9.12%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$102M
AUM Growth
+$102M
(+14%)
Cap. Flow
+$4.77M
Cap. Flow
% of AUM
4.69%
Top 10 Holdings %
Top 10 Hldgs %
47.07%
Holding
64
New
3
Increased
23
Reduced
5
Closed
4
Top Buys
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$631K |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$589K |
| 3 |
United Therapeutics
UTHR
|
$481K |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$336K |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$306K |
Top Sells
| 1 |
KITE
Kite Pharma, Inc.
KITE
|
$613K |
| 2 |
Myriad Genetics
MYGN
|
$527K |
| 3 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
$404K |
| 4 |
Iovance Biotherapeutics
IOVA
|
$220K |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$192K |
Sector Composition
| 1 | Healthcare | 78.98% |
| 2 | Real Estate | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $7.99M | 7.17% | 130,500 | – | – |
|
2
Bristol-Myers Squibb
BMY
$96B
| $5.74M | 5.15% | 90,000 | – | – |
|
3
SPDR S&P Biotech ETF
XBI
$5.07B
| $5.63M | 5.05% | 65,000 | – | – |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $5.58M | 5% | 47,459 -1,636 | -3% | -$192K |
|
5
Merck
MRK
$210B
| $5.36M | 4.81% | 83,700 | – | – |
|
6
iShares Biotechnology ETF
IBB
$5.6B
| $4.17M | 3.74% | 12,500 | – | – |
|
7
AstraZeneca
AZN
$248B
| $4.07M | 3.65% | 120,000 | – | – |
|
8
Pfizer
PFE
$141B
| $4.01M | 3.6% | 112,300 | – | – |
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $2.78M | 2.49% | 18,274 -720 | -4% | -$109K |
|
10
Nektar Therapeutics
NKTR
$568M
| $2.5M | 2.25% | 104,328 +7,129 | +7% | +$171K |
|
11
Alkermes
ALKS
$4.78B
| $2.45M | 2.2% | 48,244 +5,621 | +13% | +$286K |
|
12
GSK
GSK
$79.9B
| $2.44M | 2.19% | 60,000 | – | – |
|
|
CELG
13
DELISTED
Celgene Corp
CELG
| $2.36M | 2.12% | 16,177 +1,833 | +13% | +$267K |
|
14
Incyte
INCY
$16.5B
| $2.35M | 2.11% | 20,148 +2,316 | +13% | +$270K |
|
15
Mettler-Toledo International
MTD
$26.8B
| $2.25M | 2.02% | 3,594 | – | – |
|
|
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.25M | 2.01% | 41,263 +6,170 | +18% | +$336K |
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $2.24M | 2.01% | 44,183 +316 | +0.7% | +$16K |
|
18
Illumina
ILMN
$15.8B
| $2.24M | 2.01% | 11,235 +1,320 | +13% | +$263K |
|
19
Agios Pharmaceuticals
AGIO
$2.19B
| $2.23M | 2% | 33,347 +3,865 | +13% | +$258K |
|
20
Amgen
AMGN
$155B
| $2.13M | 1.91% | 11,406 +1,585 | +16% | +$296K |
|
|
RXDX
21
DELISTED
Ignyta, Inc.
RXDX
| $2.11M | 1.89% | 170,500 | – | – |
|
22
Biogen
BIIB
$19.4B
| $2.09M | 1.88% | 6,687 +910 | +16% | +$285K |
|
23
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.04M | 1.83% | 4,561 +29 | +0.6% | +$13K |
|
24
Qiagen
QGEN
$10.1B
| $2.03M | 1.82% | 64,421 +7,625 | +13% | +$240K |
|
25
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.86M | 1.66% | 19,926 +3,164 | +19% | +$295K |
|